Oncopeptides AB (publ)
ONPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $32 | $35 | $8 | $118 |
| % Growth | -10.1% | 321.5% | -92.9% | – |
| Cost of Goods Sold | $3 | -$1 | $0 | $53 |
| Gross Profit | $29 | $36 | $8 | $65 |
| % Margin | 91.6% | 103.1% | 99.9% | 55.1% |
| R&D Expenses | $121 | $107 | $218 | $680 |
| G&A Expenses | $61 | $69 | $84 | $175 |
| SG&A Expenses | $197 | $188 | $142 | $874 |
| Sales & Mktg Exp. | $136 | $120 | $58 | $698 |
| Other Operating Expenses | -$6 | -$6 | $0 | $0 |
| Operating Expenses | $312 | $290 | $358 | $1,486 |
| Operating Income | -$283 | -$253 | -$349 | -$1,421 |
| % Margin | -895.8% | -719.6% | -4,181.3% | -1,201.2% |
| Other Income/Exp. Net | -$1 | $5 | $12 | -$0 |
| Pre-Tax Income | -$284 | -$248 | -$338 | -$1,421 |
| Tax Expense | $0 | $1 | $0 | $9 |
| Net Income | -$285 | -$249 | -$338 | -$1,430 |
| % Margin | -899.3% | -707.3% | -4,044.9% | -1,209.1% |
| EPS | -1.87 | -2.76 | -4.11 | -19 |
| % Growth | 32.2% | 32.8% | 78.4% | – |
| EPS Diluted | -1.87 | -2.76 | -4.11 | -19 |
| Weighted Avg Shares Out | 153 | 90 | 82 | 75 |
| Weighted Avg Shares Out Dil | 153 | 90 | 82 | 75 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $9 | $3 | $0 |
| Interest Expense | $13 | $6 | $1 | $1 |
| Depreciation & Amortization | $0 | $11 | $17 | $21 |
| EBITDA | -$283 | -$232 | -$320 | -$1,405 |
| % Margin | -895.8% | -657.6% | -3,825.7% | -1,188.1% |